Lipid Lowering Therapy with Combination of Niacin and Statin in Women: Age-Related Endothelial Effects
Table 2
Variable
Visit
Niacin plus statin group
Placebo plus statin group
TC (mg/dL)
Entry
191.1 (17.1)
202.5 (31.0)
Exit
188.9 (20.3)
198.4 (26.9)
LDL-C-C (mg/dL)
Entry
100.6 (15.2)
113.0 (28.1)
Exit
84.8 (18.0)*
105.6 (17.5)†
HDL-C-C (mg/dL)
Entry
55.5 (10.3)
59.5 (12.2)
Exit
75.4 (18.9)*
60.3 (11.6)†
TG (mg/dL)
Entry
174.7 (85.1)
150.2 (71.4)
Exit
144.6 (75.32)*
162.8 (73.4)
IL-6 (pg/mL)
Entry
1.69 (0.53)
2.68 (4.17)
Exit
2.11 (0.84)
2.66 (4.33)
TNF- (pg/mL)
Entry
2.30 (0.86)
2.97 (3.68)
Exit
3.91 (4.32)
3.11 (3.21)
hsCRP (mg/L)
Entry
4.11 (2.96)
3.99 (3.69)
Exit
4.28 (3.88)
4.71 (6.23)
Data shown as group means (standard deviation). Significant () change within a group between entry and exit; Significant () difference between groups at exit. TC: total cholesterol; LDL-C-C: low-density lipoprotein cholesterol; HDL-C-C: high-density lipoprotein cholesterol; TG: triglycerides; IL-6: interleukin 6; TNF-: tumor necrosis factor alpha; hsCRP: high sensitivity C-reactive protein.
